Treatment of ocular hypertension
    11.
    发明授权
    Treatment of ocular hypertension 失效
    眼高压治疗

    公开(公告)号:US5432174A

    公开(公告)日:1995-07-11

    申请号:US162386

    申请日:1993-12-07

    CPC分类号: A61K31/557 Y10S514/913

    摘要: A method for the treatment of ocular hypertension which comprises administering, to a subject in need of such treatment,(a) a .beta.-adrenergic blocker at the enhancement phase of aqueous humor production, and(b) a prostanoic acid compound at the suppression phase of aqueous humor production, andin an amount effective in treatment of ocular hypertension.

    摘要翻译: 一种治疗眼高血压的方法,其包括向需要这种治疗的受试者施用(a)在房水生成增强阶段的β-肾上腺素能阻滞剂,和(b)抑制阶段的前列腺酸化合物 的房水产生,并且有效治疗高眼压症的量。

    Prostaglandins of the F series
    13.
    发明授权
    Prostaglandins of the F series 失效
    F系列前列腺素

    公开(公告)号:US5591887A

    公开(公告)日:1997-01-07

    申请号:US361712

    申请日:1994-12-22

    申请人: Ryuzo Ueno Ryuji Ueno

    发明人: Ryuzo Ueno Ryuji Ueno

    IPC分类号: A61K31/557 C07C405/00

    CPC分类号: C07C405/00 A61K31/557

    摘要: The present invention provides new compounds, 13,14-dihydro-15-keto-PGFs, and vassopressors containing them, which raise blood pressure without substantial ephemeral depression of blood pressure, trachea or enteron contraction effect inherent in usual PGFs.

    摘要翻译: 本发明提供了新的化合物,13,14-二氢-15-酮-PGFs和含有它们的旁通加压剂,其可以提高血压,而没有普通PGF固有的血压,气管或肠内收缩作用的实质性短暂抑制。

    Ocular hypotensive agents
    15.
    发明授权
    Ocular hypotensive agents 失效
    眼低血压药

    公开(公告)号:US5194429A

    公开(公告)日:1993-03-16

    申请号:US615515

    申请日:1990-11-19

    IPC分类号: A61K31/557

    CPC分类号: A61K31/557 Y10S514/913

    摘要: The present invention relates to an ocular hypotensive composition and a composition for treatment of glaucoma which comprising an amount of 20-substituted-PGs or 20-substituted-15-keto-PGs effective as an ocular hypotensive agent; these compounds exhibit no or little side effects such as transient ocular hypertensive response, hyperemia of conjunctiva or of iris, dacryops, lema, closed eye and the like.

    摘要翻译: 本发明涉及一种眼部降血压药物组合物和治疗青光眼的组合物,其含有作为眼部降压药有效的20-取代-GG或20-取代-15-酮-PG的量; 这些化合物没有表现出暂时性高眼压反应,结膜充血或虹膜,泪囊虫,莱玛,闭眼等副作用。

    Ocular hypotensive agents
    16.
    发明授权
    Ocular hypotensive agents 失效
    眼低血压药

    公开(公告)号:US5166178A

    公开(公告)日:1992-11-24

    申请号:US760269

    申请日:1991-09-16

    申请人: Ryuzo Ueno Ryuji Ueno

    发明人: Ryuzo Ueno Ryuji Ueno

    IPC分类号: A61K31/557 C07C405/00

    摘要: The present invention relates to ocular hypotensive agents which contains 13,14-dihydro-15-keto-prostagrandins, which shows no transient ocular hypertensive response that PGs usually show.

    摘要翻译: 本发明涉及含有13,14-二氢-15-酮 - 前列腺素的低血压药,其不显示PG通常显示的暂时性高眼压反应。

    Prostaglandins E and anti-ulcers containing same
    17.
    发明授权
    Prostaglandins E and anti-ulcers containing same 失效
    前列腺素E和含有相同的抗溃疡

    公开(公告)号:US5166174A

    公开(公告)日:1992-11-24

    申请号:US700895

    申请日:1991-05-13

    IPC分类号: C07C405/00

    CPC分类号: C07C405/00

    摘要: The novel 13,14-dihydro-15-keto prostaglandins E of the invention have remarkable preventive effects against ulcers. Further, the novel 13,14-dihydro-15-keto-prostaglandins E of the invention have an advantage that they have none of side effects which prostaglandin E intrinsically has, or can remarakably reduce such effects of the prostaglandin E. Therefore, the novel 13,14-dihydro-15-keto prostaglandins E of the invention are effective for animal and human use for treatment and prevention of ulcers, such as duodenal ulcer and gastric ulcer.

    摘要翻译: 本发明的新型13,14-二氢-15-酮前列腺素E对溃疡具有显着的预防作用。 此外,本发明的新型13,14-二氢-15-酮 - 前列腺素E具有这样的优点:它们不具有前列腺素E本身具有的副作用,或者可以再度降低前列腺素E的这种作用。因此,该小说 本发明的13,14-二氢-15-酮前列腺素E对于动物和人类用于治疗和预防溃疡如十二指肠溃疡和胃溃疡是有效的。

    Prostaglandin I analogue
    18.
    发明授权
    Prostaglandin I analogue 失效
    前列腺素I类似物

    公开(公告)号:US5107014A

    公开(公告)日:1992-04-21

    申请号:US521621

    申请日:1990-05-10

    IPC分类号: C07C59/90 C07C405/00

    CPC分类号: C07C405/0083 C07C59/90

    摘要: The present invention relates to a new prostagrandine I analogous compounds represented by the following formula (I) and (II). ##STR1## wherein R.sub.1 is a hydrogen atom or alkyl group, at least one of R.sub.2 and/or R.sub.2 ' are a halogen atom, an alkyl group, a group containing an aromatic group, a hydroxyl group or an alkoxy group providing that the R.sub.2 and R.sub.2 ' are not simultaneously hydrogen atoms or salt thereof, which compound is expected as hypotensives.

    摘要翻译: 本发明涉及由下式(I)和(II)表示的新的前列腺素I类似物。 (Ⅰ)其中R1是氢原子或烷基,R2和/或R2'中的至少一个是卤素原子,烷基,含芳基的基团,羟基 基团或烷氧基,条件是R2和R2'不同时为氢原子或其盐,该化合物预期作为低渗剂。

    Ocular hypotensive agents
    20.
    发明授权
    Ocular hypotensive agents 失效
    眼低血压药

    公开(公告)号:US06420422B1

    公开(公告)日:2002-07-16

    申请号:US08476583

    申请日:1995-06-07

    IPC分类号: A61K31455

    CPC分类号: A61K31/557 C07C405/00

    摘要: The present invention relates to an ocular hypotensive composition and a composition for treatment of glaucoma which comprising an amount of 20-substituted-PGs or 20-substituted 15-keto-PGs effective as an ocular hypotensive agent; these compounds exhibit no or little side effect such as transient ocular hypertensive response, hyperemia of conjunctiva or of iris, dacryops, lema, closed eye and the like. The present invention relates to ocular hypotensive agents which contains 13,14-dihydro-15-keto-prostagrandins, which shows no transient ocular hypertensive response that PGs usually show.

    摘要翻译: 本发明涉及一种眼部降血压药物组合物和治疗青光眼的组合物,其含有作为眼部降压药有效的20-取代的PG或20-取代的15-酮基-PG的量; 这些化合物没有或没有副作用,例如暂时性高眼压反应,结膜充血或虹膜,泪囊虫,莱马,闭眼等。本发明涉及含有13,14-二氢-15- 酮前列腺素,其不显示PG通常显示的暂时性高眼压反应。